You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmoxapine
Accession NumberDB00543  (APRD00142)
TypeSmall Molecule
GroupsApproved
DescriptionAmoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation.
Structure
Thumb
Synonyms
2-Chloro-11-(1-piperazinyl)dibenz(b,F)(1,4)oxazepine
Amoxapin
Amoxapina
Amoxapinum
Amoxepine
Desmethylloxapin
External Identifiers
  • CL 67772
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Asendin - Tab 100mgTablet100 mgOralWyeth Ayerst Canada Inc.1999-04-122002-06-10Canada
Asendin - Tab 25mgTablet25 mgOralWyeth Ayerst Canada Inc.1997-02-042000-08-02Canada
Asendin - Tab 50mgTablet50 mgOralWyeth Ayerst Canada Inc.1997-04-292001-12-12Canada
Asendin Tab 100mgTablet100 mgOralLederle Cyanamid Canada Inc.1981-12-311999-04-12Canada
Asendin Tab 25mgTablet25 mgOralLederle Cyanamid Canada Inc.1981-12-311997-08-14Canada
Asendin Tab 50mgTablet50 mgOralLederle Cyanamid Canada Inc.1981-12-311999-04-12Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmoxapineTablet25 mg/1OralActavis Pharma, Inc.1992-08-28Not applicableUs
AmoxapineTablet50 mg/1OralPhysicians Total Care, Inc.2011-05-12Not applicableUs
AmoxapineTablet50 mg/1OralActavis Pharma, Inc.1992-08-28Not applicableUs
AmoxapineTablet100 mg/1OralActavis Pharma, Inc.1992-08-28Not applicableUs
AmoxapineTablet150 mg/1OralActavis Pharma, Inc.1992-08-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdisenKun Wha
AmolifeNot Available
AmoxanWyeth KK
AsendinNot Available
AsendisNot Available
DéfanylEisai
DemoloxWyeth
OxaminePsyco Remedies
OxcapNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIR63VQ857OT
CAS number14028-44-5
WeightAverage: 313.781
Monoisotopic: 313.098189856
Chemical FormulaC17H16ClN3O
InChI KeyQWGDMFLQWFTERH-UHFFFAOYSA-N
InChI
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
IUPAC Name
13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene
SMILES
ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
Pharmacology
IndicationFor the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.
Structured Indications
PharmacodynamicsAmoxapine is a tricyclic antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzodiazepines, dibenzocycloheptenes, and dibenzoxepines. It has a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of nor-epinephirine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine
Mechanism of actionAmoxapine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinunknown
inhibitor
HumanP23975 details
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
D(2) dopamine receptorProteinunknown
antagonist
HumanP14416 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Gamma-aminobutyric acid receptor subunit alpha-1Proteinunknown
antagonist
HumanP14867 details
5-hydroxytryptamine receptor 2AProteinunknown
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
5-hydroxytryptamine receptor 6Proteinunknown
antagonist
HumanP50406 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Alpha-1 adrenergic receptorProtein groupunknown
antagonist
Humannot applicabledetails
Muscarinic acetylcholine receptorProtein groupunknown
antagonist
Humannot applicabledetails
5-hydroxytryptamine receptor 2BProteinunknown
antagonist
HumanP41595 details
5-hydroxytryptamine receptor 3AProteinunknown
antagonist
HumanP46098 details
5-hydroxytryptamine receptor 1AProteinunknown
antagonist
HumanP08908 details
5-hydroxytryptamine receptor 1BProteinunknown
antagonist
HumanP28222 details
Alpha-2 adrenergic receptorProtein groupunknown
antagonist
Humannot applicabledetails
Histamine H4 receptorProteinunknown
binder
HumanQ9H3N8 details
GABA-A receptor (anion channel)Protein groupunknown
binder
Humannot applicabledetails
Sodium-dependent dopamine transporterProteinunknown
binder
HumanQ01959 details
Related Articles
AbsorptionRapidly and almost completely absorbed from the GI tract. Peak plasma concentrations occur within 1-2 hours of oral administration of a single dose.
Volume of distribution

Widely distributed in body tissues with highest concentrations found in lungs, spleen, kidneys, heart, and brain. Lower concentrations can be detected in testes and muscle.

Protein bindingIn vitro tests show that amoxapine binding to human plasma proteins is approximately 90%.
Metabolism

Amoxapine is almost completely metabolized in the liver to its major metabolite, 8-hydroxyamoxapine, and a minor metabolite, 7-hydroxyamoxapine. Both metabolites are phamacologically inactive and have half-lives of approximately 30 and 6.5 hours, respectively.

SubstrateEnzymesProduct
Amoxapine
Not Available
7-hydroxyamoxapineDetails
Amoxapine
Not Available
8-hydroxyamoxapineDetails
Route of elimination60-69% of a single orally administered dose of amoxapine is excreted in urine, principally as conjugated metabolites. 7-18% of the dose is excrete feces mainly as unconjugated metabolites. Less than 5% of the dose is excreted as unchanged drug in urine.
Half life8 hours
ClearanceNot Available
ToxicityToxic manifestations of amoxapine overdosage differ significantly from those of other tricyclic antidepressants. Serious cardiovascular effects are seldom if ever observed. However, CNS effects, particularly grand mal convulsions, occur frequently, and treatment should be directed primarily toward prevention or control of seizures. Status epilepticus may develop and constitutes a neurologic emergency. Coma and acidosis are other serious complications of substantial amoxapine overdosage in some cases. Renal failure may develop two to five days after toxic overdose in patients who may appear otherwise recovered. Acute tubular necrosis with rhabdomuolysis and myolobinurla is the most common renal complication in such cases. This reaction probably occurs in less than 5% of overdose cases, and typically in those who have experienced multiple seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Amoxapine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amoxapine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Amoxapine.Experimental
AbirateroneThe serum concentration of Amoxapine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Amoxapine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amoxapine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Acetophenazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Amoxapine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amoxapine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Amoxapine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Amoxapine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Amoxapine.Approved, Vet Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Almotriptan.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Amoxapine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amoxapine.Approved, Illicit, Investigational
AmiodaroneAmoxapine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Amoxapine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Amoxapine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amoxapine.Approved, Illicit
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Amoxapine.Experimental
AnagrelideAmoxapine may increase the QTc-prolonging activities of Anagrelide.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amoxapine.Approved, Investigational
Arsenic trioxideAmoxapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherAmoxapine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Amoxapine.Approved
AsenapineAmoxapine may increase the QTc-prolonging activities of Asenapine.Approved
AtomoxetineThe metabolism of Amoxapine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Amoxapine.Vet Approved
AzelastineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Azelastine.Approved
AzithromycinAmoxapine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Amoxapine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Amoxapine.Illicit
BedaquilineAmoxapine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Amoxapine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amoxapine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Amoxapine.Approved
BetaxololThe metabolism of Amoxapine can be decreased when combined with Betaxolol.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bifeprunox.Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Amoxapine.Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Amoxapine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amoxapine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amoxapine.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Amoxapine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amoxapine.Approved, Investigational
BuprenorphineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Amoxapine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Amoxapine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amoxapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Amoxapine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Amoxapine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Amoxapine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Amoxapine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amoxapine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amoxapine.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amoxapine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Amoxapine.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Amoxapine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Amoxapine.Withdrawn
CelecoxibThe metabolism of Amoxapine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibAmoxapine may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Amoxapine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amoxapine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amoxapine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amoxapine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amoxapine.Approved
ChloroquineAmoxapine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Chlorphenamine.Approved
ChlorpromazineAmoxapine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amoxapine.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Amoxapine.Approved
CholecalciferolThe metabolism of Amoxapine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Amoxapine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Amoxapine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amoxapine.Approved, Vet Approved
CiprofloxacinAmoxapine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideAmoxapine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramAmoxapine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinAmoxapine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Amoxapine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clidinium.Approved
ClobazamThe metabolism of Amoxapine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Amoxapine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amoxapine.Approved, Illicit
ClotrimazoleThe metabolism of Amoxapine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineAmoxapine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Amoxapine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Amoxapine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amoxapine.Approved, Illicit
CrizotinibAmoxapine may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Amoxapine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amoxapine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amoxapine.Investigational
DarifenacinThe metabolism of Amoxapine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Amoxapine can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Amoxapine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Amoxapine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amoxapine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Amoxapine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amoxapine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amoxapine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amoxapine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amoxapine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amoxapine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amoxapine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amoxapine.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amoxapine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amoxapine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amoxapine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amoxapine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Amoxapine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amoxapine.Approved, Illicit
DisopyramideAmoxapine may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideAmoxapine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronAmoxapine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneAmoxapine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Amoxapine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Amoxapine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Illicit
DronedaroneAmoxapine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Amoxapine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amoxapine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amoxapine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Amoxapine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Amoxapine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Amoxapine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amoxapine.Approved, Investigational
EliglustatAmoxapine may increase the QTc-prolonging activities of Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amoxapine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Amoxapine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergotamine.Approved
ErythromycinAmoxapine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramAmoxapine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amoxapine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amoxapine.Approved
EthanolAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amoxapine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amoxapine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amoxapine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amoxapine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Amoxapine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Amoxapine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Amoxapine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Amoxapine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Amoxapine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Amoxapine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amoxapine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fexofenadine.Approved
FlecainideAmoxapine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amoxapine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amoxapine.Approved, Illicit
FluoxetineAmoxapine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolAmoxapine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amoxapine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amoxapine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amoxapine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amoxapine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Amoxapine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Amoxapine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amoxapine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Amoxapine is combined with gabapentin enacarbil.Approved
Gadobenic acidAmoxapine may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amoxapine.Approved, Illicit
GemifloxacinAmoxapine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Amoxapine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Amoxapine.Approved, Illicit
GoserelinAmoxapine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronAmoxapine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amoxapine.Approved, Illicit, Withdrawn
HaloperidolAmoxapine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amoxapine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Amoxapine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amoxapine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Amoxapine.Approved
HydrocodoneAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amoxapine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
IbutilideAmoxapine may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneAmoxapine may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Amoxapine.Approved
IndalpineIndalpine may increase the serotonergic activities of Amoxapine.Investigational, Withdrawn
IndinavirThe metabolism of Amoxapine can be decreased when combined with Indinavir.Approved
Ioflupane I-123Amoxapine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Amoxapine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Amoxapine.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amoxapine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amoxapine.Approved, Vet Approved
IsoniazidThe metabolism of Amoxapine can be decreased when combined with Isoniazid.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amoxapine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amoxapine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amoxapine.Approved
KetoconazoleThe metabolism of Amoxapine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lamotrigine.Approved, Investigational
LenvatinibAmoxapine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideAmoxapine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amoxapine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levodopa.Approved
LevofloxacinAmoxapine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amoxapine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amoxapine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amoxapine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Amoxapine is combined with Linezolid.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Amoxapine.Illicit
LopinavirAmoxapine may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Amoxapine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amoxapine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lorcaserin.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amoxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Amoxapine.Investigational
LumefantrineAmoxapine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amoxapine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Amoxapine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Amoxapine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amoxapine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Amoxapine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amoxapine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amoxapine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amoxapine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Amoxapine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Amoxapine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amoxapine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amoxapine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Amoxapine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amoxapine.Approved
MethotrimeprazineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amoxapine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Amoxapine.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amoxapine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Metoclopramide.Approved, Investigational
MetoprololThe metabolism of Amoxapine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineAmoxapine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Amoxapine.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Amoxapine.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Amoxapine is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Amoxapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Investigational
MirabegronThe metabolism of Amoxapine can be decreased when combined with Mirabegron.Approved
MirtazapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amoxapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Amoxapine.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Amoxapine.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Amoxapine.Approved, Investigational
MoxifloxacinAmoxapine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amoxapine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Naratriptan.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nefazodone.Approved, Withdrawn
NevirapineThe metabolism of Amoxapine can be decreased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Amoxapine.Withdrawn
NicardipineThe metabolism of Amoxapine can be decreased when combined with Nicardipine.Approved
NilotinibAmoxapine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amoxapine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Amoxapine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Amoxapine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Amoxapine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Amoxapine.Withdrawn
OfloxacinAmoxapine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amoxapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Olopatadine.Approved
OndansetronAmoxapine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Amoxapine.Approved, Illicit
OrphenadrineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Amoxapine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amoxapine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amoxapine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amoxapine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amoxapine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amoxapine.Approved, Investigational, Vet Approved
PaliperidoneAmoxapine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Amoxapine.Approved, Investigational
PanobinostatThe serum concentration of Amoxapine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Amoxapine.Approved
ParoxetineThe metabolism of Amoxapine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibAmoxapine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Amoxapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineAmoxapine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amoxapine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amoxapine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Amoxapine.Investigational
PerflutrenAmoxapine may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Amoxapine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amoxapine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amoxapine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amoxapine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Amoxapine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amoxapine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Amoxapine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Amoxapine.Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Amoxapine.Approved, Vet Approved
PimozideAmoxapine may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amoxapine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Amoxapine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Amoxapine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pomalidomide.Approved
PramipexoleAmoxapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Amoxapine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Amoxapine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amoxapine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amoxapine.Approved
PrimaquineAmoxapine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Primidone.Approved, Vet Approved
ProcainamideAmoxapine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amoxapine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amoxapine.Approved, Vet Approved
PromazineAmoxapine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Promethazine.Approved
PropafenoneAmoxapine may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amoxapine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Amoxapine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amoxapine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Amoxapine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Amoxapine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amoxapine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Amoxapine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Amoxapine.Approved, Illicit
QuetiapineAmoxapine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineAmoxapine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineAmoxapine may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Amoxapine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amoxapine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amoxapine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amoxapine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amoxapine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Amoxapine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Amoxapine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Rizatriptan.Approved
RolapitantThe metabolism of Amoxapine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Amoxapine.Vet Approved
RopiniroleAmoxapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amoxapine.Approved
RotigotineAmoxapine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amoxapine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amoxapine.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Amoxapine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Amoxapine is combined with Sage 547.Investigational
SaquinavirAmoxapine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amoxapine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Amoxapine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Amoxapine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amoxapine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
SotalolAmoxapine may increase the QTc-prolonging activities of Sotalol.Approved
StiripentolThe metabolism of Amoxapine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amoxapine.Approved, Investigational
SulfisoxazoleAmoxapine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amoxapine.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sumatriptan.Approved, Investigational
SuvorexantAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Amoxapine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Amoxapine.Approved
TelavancinAmoxapine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinAmoxapine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amoxapine.Approved
TerbinafineThe metabolism of Amoxapine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineAmoxapine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Amoxapine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amoxapine.Investigational
ThalidomideAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amoxapine.Approved, Vet Approved
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Amoxapine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amoxapine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Thioproperazine.Approved
ThioridazineAmoxapine may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amoxapine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Amoxapine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Amoxapine.Vet Approved
TipranavirThe metabolism of Amoxapine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amoxapine.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Amoxapine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Amoxapine.Approved
ToremifeneAmoxapine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Amoxapine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amoxapine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amoxapine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amoxapine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amoxapine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amoxapine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Amoxapine.Approved
TropisetronTropisetron may increase the serotonergic activities of Amoxapine.Investigational
Uc1010The risk or severity of adverse effects can be increased when Amoxapine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Amoxapine.Approved, Investigational
VandetanibAmoxapine may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibAmoxapine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Amoxapine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Vilazodone.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Amoxapine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amoxapine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ziconotide.Approved
ZimelidineZimelidine may increase the serotonergic activities of Amoxapine.Withdrawn
ZiprasidoneAmoxapine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Amoxapine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amoxapine.Approved, Investigational
ZolpidemAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amoxapine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Amoxapine.Approved
ZuclopenthixolAmoxapine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.
References
Synthesis Reference

Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; US. Patent 3,663,696; May 16, 1972; assigned to American Cyanamid Company
Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; U.S. Patent 3,681,357; August 1, 1972; assigned to American Cyanamid Company

US3663696
General ReferencesNot Available
External Links
ATC CodesN06AA17
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9928
Blood Brain Barrier+0.988
Caco-2 permeable-0.5488
P-glycoprotein substrateSubstrate0.8068
P-glycoprotein inhibitor IInhibitor0.7622
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.6414
CYP450 2C9 substrateNon-substrate0.7682
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5168
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5472
Ames testNon AMES toxic0.7277
CarcinogenicityNon-carcinogens0.8159
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9781 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6376
hERG inhibition (predictor II)Inhibitor0.7874
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sandoz inc
  • Watson laboratories inc
  • Lederle laboratories div american cyanamid co
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral100 mg
TabletOral25 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Amoxapine 30 150 mg tablet Bottle82.15USD bottle
Amoxapine 150 mg tablet2.63USD tablet
Amoxapine 100 mg tablet1.7USD tablet
Amoxapine 50 mg tablet1.02USD tablet
Amoxapine 25 mg tablet0.63USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point175-176Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; US. Patent 3,663,696; May 16, 1972; assigned to American Cyanamid Company Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; U.S. Patent 3,681,357; August 1, 1972; assigned to American Cyanamid Company
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.171 mg/mLALOGPS
logP2.82ALOGPS
logP3.08ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)8.83ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area36.86 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity89.82 m3·mol-1ChemAxon
Polarizability32.82 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-052b-4490000000-6bbd0d2c0c8fe332c636View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzoxazepines. These are compounds containing a dibenzoxazepine moiety, which consists of two benzene connected by an oxazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxazepines
Sub ClassDibenzoxazepines
Direct ParentDibenzoxazepines
Alternative Parents
Substituents
  • Dibenzoxazepine
  • Diaryl ether
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Spurlock G, Buckland P, O'Donovan M, McGuffin P: Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter. Neuropharmacology. 1994 Mar-Apr;33(3-4):433-40. [PubMed:7984281 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5. [PubMed:1966571 ]
  2. Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. [PubMed:11180191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. [PubMed:11180191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
  2. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5. [PubMed:1966571 ]
  2. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Richelson E: Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clin Proc. 1983 Jan;58(1):40-6. [PubMed:6130192 ]
  2. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Glusa E, Pertz HH: Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 2000 Jun;130(3):692-8. [PubMed:10821800 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. [PubMed:16135699 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. [PubMed:16135699 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Components:
NameUniProt IDDetails
Muscarinic acetylcholine receptor M1P11229 Details
Muscarinic acetylcholine receptor M2P08172 Details
Muscarinic acetylcholine receptor M3P20309 Details
Muscarinic acetylcholine receptor M4P08173 Details
Muscarinic acetylcholine receptor M5P08912 Details
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Glusa E, Pertz HH: Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 2000 Jun;130(3):692-8. [PubMed:10821800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Gozlan H, Saddiki-Traki F, Merahi N, Laguzzi R, Hamon M: [Preclinical pharmacology of amoxapine and amitriptyline. Implications of serotoninergic and opiodergic systems in their central effect in rats]. Encephale. 1991 Dec;17 Spec No 3:415-22. [PubMed:1666997 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Gozlan H, Saddiki-Traki F, Merahi N, Laguzzi R, Hamon M: [Preclinical pharmacology of amoxapine and amitriptyline. Implications of serotoninergic and opiodergic systems in their central effect in rats]. Encephale. 1991 Dec;17 Spec No 3:415-22. [PubMed:1666997 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Gozlan H, Saddiki-Traki F, Merahi N, Laguzzi R, Hamon M: [Preclinical pharmacology of amoxapine and amitriptyline. Implications of serotoninergic and opiodergic systems in their central effect in rats]. Encephale. 1991 Dec;17 Spec No 3:415-22. [PubMed:1666997 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R: Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21. Epub 2005 Jun 9. [PubMed:15947036 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5. [PubMed:1966571 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  2. PDSP Ki Database [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Shin HC, Kim HR, Cho HJ, Yi H, Cho SM, Lee DG, Abd El-Aty AM, Kim JS, Sun D, Amidon GL: Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos. 2009 Nov;30(8):411-21. doi: 10.1002/bdd.675. [PubMed:19746353 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23